Skip to main content

Table 1 Characteristics of the included studies

From: Prognostic value of CD44 expression in patients with hepatocellular carcinoma: meta-analysis

Study Patient’s country Ethnicity Year Time of collection Pathological stage Method Number of patients Age in years Follow-up months Cut-off for CD44 positive Survival analysis
Endo et al. [18] Japan Asian 2000 ND ND IHC 107 17–80 80 >0 %
staining
OS
Huang et al. [22] China Asian 2001 1995–1999 I–IV IHC 51 36–72 48 >0 %
staining
OS
Su et al. [27] China Asian 2006 1996–1999 I–IV IHC 40 32–70 36 >0 %
staining
OS
Yang et al. [28] China Asian 2008 1997–2000 I–IV IHC 302 26–75 121 >10 %
staining
OS; DFS
Zhang et al. [21] China Asian 2008 2001–2004 I–IV IHC 50 21–68 ND >20 %
staining
OS
Peng et al. [23] China Asian 2010 2005–2006 ND IHC 76 19–69 36 >25 %
staining
OS
Ryu et al. [17] Korea Asian 2011 1990–2003 I–IV IHC 260 ND 137 >10 %
staining
OS; DFS
Tovuu et al. [25] Japan Asian 2012 2005–2009 I–IV RT–PCR 48 ND 48 Median OS; DFS
Mima et al. [16, 19] Japan Asian 2012 2004–2007 I–IV IHC 150 ND 60 >0 %
staining
OS; DFS
Zhou et al. [24] China Asian 2012 2007–2010 I–III RT–PCR 323 ND 74 Median OS; DFS
Mima et al. [16, 19] Japan Asian 2012 2004–2007 I–IV IHC 235 ND 60 >50 %
staining
OS; DFS
Chen et al. [26] China Asian 2014 2005–2008 I–IV IHC 387 ND 96 >10 %
staining
OS
Cao et al. [29] China Asian 2014 2005–2011 ND IHC 46 22–79 85 >25 %
staining
OS
Hu et al. [20] China Asian 2014 2006–2007 I–III IHC 160 29–72 84 >10 %
staining
OS; DFS